Literature DB >> 16243488

LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain.

Daniel Korr1, Luisella Toschi, Peter Donner, Hans-Dieter Pohlenz, Bertolt Kreft, Bertram Weiss.   

Abstract

Human leucine-rich repeat kinase 1 (LRRK1) is a multi-domain protein of unknown function belonging to the ROCO family of complex proteins. Here, we report the molecular characterization of human LRRK1 and show, for the first time, that LRRK1 is both a functional protein kinase and a GDP/GTP-binding protein. Binding of GTP to LRRK1 is specific, requires the GTPase-like Roc domain, and leads to a stimulation of LRRK1 kinase activity. LRRK1 is the first example of a GTP-regulated protein kinase harboring both the kinase effector domain and the GTP-binding regulatory domain. Hence, we propose a model in which LRRK1 cycles between a GTP-bound active and a GDP-bound inactive state. Moreover, we mutated LRRK1 to mimic mutations previously identified in LRRK2/dardarin, the only human paralogue of LRRK1, that have been linked to autosomal-dominant parkinsonism. We demonstrate that three of four mutations analyzed significantly downregulate LRRK1 kinase activity. Ultimately, the results presented for LRRK1 may contribute to the elucidation of LRRK2's role in the pathogenesis of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16243488     DOI: 10.1016/j.cellsig.2005.08.015

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  56 in total

1.  GTP-binding protein-like domain of AGAP1 is protein binding site that allosterically regulates ArfGAP protein catalytic activity.

Authors:  Ruibai Luo; Itoro O Akpan; Ryo Hayashi; Marek Sramko; Valarie Barr; Yoko Shiba; Paul A Randazzo
Journal:  J Biol Chem       Date:  2012-03-27       Impact factor: 5.157

2.  The ROCO kinase QkgA is necessary for proliferation inhibition by autocrine signals in Dictyostelium discoideum.

Authors:  Jonathan E Phillips; Richard H Gomer
Journal:  Eukaryot Cell       Date:  2010-08-13

3.  Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant.

Authors:  Veronique Daniëls; Renée Vancraenenbroeck; Bernard M H Law; Elisa Greggio; Evy Lobbestael; Fangye Gao; Marc De Maeyer; Mark R Cookson; Kirsten Harvey; Veerle Baekelandt; Jean-Marc Taymans
Journal:  J Neurochem       Date:  2011-01       Impact factor: 5.372

4.  Distal Partial Trisomy 15q26 and Partial Monosomy 16p13.3 in a 36-Year-Old Male with Clinical Features of Both Chromosomal Abnormalities.

Authors:  Devin M Cox; Merlin G Butler
Journal:  Cytogenet Genome Res       Date:  2015-04-08       Impact factor: 1.636

5.  Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson's disease.

Authors:  Julie P Taylor; Mary M Hulihan; Jennifer M Kachergus; Heather L Melrose; Sarah J Lincoln; Kelly M Hinkle; Jeremy T Stone; Owen A Ross; Robert Hauser; Jan Aasly; Thomas Gasser; Haydeh Payami; Zbigniew K Wszolek; Matthew J Farrer
Journal:  Neurogenetics       Date:  2007-01-16       Impact factor: 2.660

Review 6.  Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative disease.

Authors:  Robert E Burke
Journal:  Pharmacol Ther       Date:  2007-02-27       Impact factor: 12.310

7.  Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway.

Authors:  Anthony K F Liou; Rehana K Leak; Lihua Li; Michael J Zigmond
Journal:  Neurobiol Dis       Date:  2008-07-08       Impact factor: 5.996

8.  Identification of biallelic LRRK1 mutations in osteosclerotic metaphyseal dysplasia and evidence for locus heterogeneity.

Authors:  Aritoshi Iida; Weirong Xing; Martine K F Docx; Tomoki Nakashima; Zheng Wang; Mamori Kimizuka; Wim Van Hul; Dietz Rating; Jürgen Spranger; Hirohumi Ohashi; Noriko Miyake; Naomichi Matsumoto; Subburaman Mohan; Gen Nishimura; Geert Mortier; Shiro Ikegawa
Journal:  J Med Genet       Date:  2016-04-07       Impact factor: 6.318

Review 9.  LRRK2 Pathways Leading to Neurodegeneration.

Authors:  Mark R Cookson
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

10.  The WD40 domain is required for LRRK2 neurotoxicity.

Authors:  Nathan D Jorgensen; Yong Peng; Cherry C-Y Ho; Hardy J Rideout; Donald Petrey; Peng Liu; William T Dauer
Journal:  PLoS One       Date:  2009-12-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.